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Edited by Lukas HuberAbstract Cannabinoids have been shown to inhibit the growth
of a broad spectrum of tumour cells. However, the molecular
mechanisms involved in that eﬀect have not been completely elu-
cidated. Here, we investigated the possible involvement of mito-
gen-activated protein kinases (MAPKs) in CB2 receptor-induced
apoptosis of human leukaemia cells. Results show that stimula-
tion of the CB2 receptor leads to p38 MAPK activation and that
inhibition of this kinase attenuates CB2 receptor-induced caspase
activation and apoptosis. These ﬁndings support a role for p38
MAPK in CB2 receptor-induced apoptosis of human leukaemia
cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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receptor1. Introduction
D9-tetrahydrocannabinol (THC) exerts a wide variety of
biological eﬀects by mimicking endogenous substances – the
endocannabinoids anandamide [1] and 2-arachidonoylglycerol
[2] – that bind to and activate speciﬁc cannabinoid receptors.
So far, two cannabinoid-speciﬁc Gi/o protein-coupled recep-
tors, CB1 and CB2, have been cloned and characterized from
mammalian tissues [3]. The CB1 receptor is particularly abun-
dant in discrete areas of the brain. In contrast, the CB2 recep-
tor was initially described to be present in the immune system
[4], although recently it has been shown that expression of this
receptor also occurs in cells from other origins [5–7].
One of the most exciting areas of research in the cannabi-
noid ﬁeld is the study of the therapeutic value of these com-
pounds [8,9]. Among these possible applications,
cannabinoids are being investigated as potential antitumoural
drugs [10]. The antitumoural actions of cannabinoids rely, at
least in part, on the ability of these compounds to induce apop-Abbreviations: Bid, BH3 interacting-domain death-agonist; tBid,
truncated Bid; ERK, extracellular signal-regulated kinase; FITC,
ﬂuorescein isothiocyanate; JNK, c-Jun N-terminal kinase; MAPK,
mitogen-activated protein kinase; PARP, poly(ADP-ribose) polymer-
ase; THC, D9-tetrahydrocannabinol; TMRM, tetramethylrhodamine
methyl ester; Dwm, mitochondrial-inner-membrane transmembrane
potential
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doi:10.1016/j.febslet.2005.08.021tosis on a wide spectrum of tumour cells [10]. Both CB1 and
CB2 receptors have been shown to mediate these cannabinoid
actions [10]. In particular, the CB2 receptor plays a major role
in the pro-apoptotic eﬀect of cannabinoids in gliomas [11], skin
carcinomas [6] and lymphomas [12], although the molecular
mechanisms responsible for this eﬀect remain unravelled.
The CB1 receptor modulates several mitogen-activated pro-
tein kinase (MAPK) pathways that are involved in the control
of cell proliferation and survival, including extracellular signal-
regulated kinase (ERK) [13], c-Jun N-terminal kinase (JNK)
and p38 MAPK [14–16]. In the present study, we investigated
the potential involvement of these signalling routes in the
mechanism of CB2 receptor-induced apoptosis.2. Materials and methods
2.1. Reagents
THC, the CB-receptor antagonists (SR141716 and SR144528) and
JWH-133 were kind gifts from Dr. Javier Ferna´ndez-Ruiz (Complu-
tense University, Madrid), Sanoﬁ-Aventis (Montpellier, France) and
Dr. John W. Huﬀman (Clemson University, SC), respectively. The
ﬂuorescent probes Hoechst 33258 and tetramethylrhodamine metyl
ester (TMRM) as well as annexin V-ﬂuorescein isothiocyanate
(FITC) were from Molecular Probes (Leiden, The Netherlands).
Anti-p38 MAPK, anti-phospho-p38 MAPK, anti-phospho-ERK, anti-
phospho-JNK, anti-caspase 3 and anti-poly(ADP-ribose) polymerase
(PARP) antibodies were from Cell Signalling (Berverly, MA). Anti-
a-tubulin was from Sigma Chemical Co. (St. Louis, MO), anti-BH3
interacting-domain death-agonist (Bid) antibody was from R&D Sys-
tems (Minneapolis, MN), and anti-cytochrome c and anti-Bcl-x anti-
bodies were from BD Pharmingen (San Diego, CA). PD169316 was
from Calbiochem (Darmstadt, Germany).
2.2. Cell culture and viability
Exponentially growing Jurkat cells were cultured in RPMI 1640
medium containing 10% heat-inactivated foetal bovine serum,
10 mM HEPES, 5 U/mL penicillin and 5 mg/mL streptomycin. Jurkat
cells stably transfected with Bcl-xL expression vector [17] were main-
tained in the same medium supplemented with 1 mg/mL G418. Cells
were transferred to a serum-free medium 30 min before performing
the diﬀerent treatments.
2.3. Nuclear DNA content
Cells were collected by centrifugation at 1500 · g for 5 min, washed
once, and incubated for 30 min at room temperature in PBS containing
1% (w/v) BSA, 30% ethanol and 5 lg/mL Hoechst 33342. Fluorescence
intensity was analyzed using a LSR ﬂow cytometer (Becton Dickinson,
San Jose, CA).
2.4. Quantitative real time PCR
Total RNA was isolated using the RNeasy Protect kit (Qiagen,
Hilden, Germany) including a DNase digestion step using the
RNase-free DNase kit (Qiagen). cDNA was obtained using theblished by Elsevier B.V. All rights reserved.
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CB1 and CB2 were obtained from Applied Biosystems (Foster City,
California). Experiments were routinely performed including a nega-
tive control (no cDNA) as well as a positive control for CB1 recep-
tor mRNA expression (cDNA obtained from RNA of the human
astrocytoma cell line U373MG).
2.5. Apoptosis
Cells (approximately 0.55 · 106 cells per assay) were collected by
centrifugation at 1500 · g for 5 min, washed once, and incubated
for 30 min at room temperature in 50 lL of binding buﬀer
(10 mM HEPES, pH 7.4, 2.5 mM CaCl2, 140 mM NaCl) supple-
mented with 3 lL annexin V-FITC. After incubation for 1 addi-
tional minute with the same medium containing 4.5 lg/mL
propidium iodide, ﬂuorescence intensity was analyzed using a FACS
Calibur ﬂow cytometer. Ten thousand cells were recorded in each
analysis.
2.6. Mitochondrial transmembrane potential
Cells (approximately 0.55 · 106 cells per assay) were collected by
centrifugation at 1500 · g for 5 min, washed once, and incubated for
30 min at room temperature with binding buﬀer (see above) plus
0.25 lM TMRM and 3 lL annexin V-FITC. After incubation for 1
additional minute with 1 lM Hoechst 33258 – in order to discriminate
living cells – ﬂuorescence intensity was analyzed using a LSR ﬂow
cytometer. Ten thousand cells were recorded in each analysis.
2.7. Mitochondria- and cytosol-enriched fractions
They were isolated as described in [18].
2.8. Western blot
Samples (15–45 lg protein/condition) were subjected to SDS/PAGE
in 10% or 15% polyacrylamide gels and transferred to PVDF mem-
branes. Western blot analysis was performed using the corresponding
antibodies.
2.9. Caspase activity
Caspase 3/7 activity (DVEDase activity) and caspase 8 (LETDase
activity) were determined according to manufacturer instructions using
a luminogenic substrate (Caspase Glo, Promega, Madison, WI). Lum-
iniscence was determined in a Microplate Fluorescence Reader FLU-
Ostar Optima (BMG Labtech, Oﬀernburg, Germany).2.10. Statistics
Results shown represent means ± S.D. In statistical analyses of Wes-
tern blot bands, S.D. values are omitted for clarity. Statistical analysis
was performed by ANOVA with a post hoc analysis by the Student–
Neuman–Keuls test.3. Results and discussion
3.1. p38 MAPK is involved in CB2 receptor-induced apoptosis
THC has been shown to induce apoptosis of human leu-
kaemia cells via the CB2 receptor [12]. We conﬁrmed by real
time quantitative PCR that CB2 was the unique cannabinoid
receptor expressed by these cells (CB2 ampliﬁcation was evi-
dent after 22 cycles whereas no ampliﬁcation of CB1 receptor
mRNA was detected after 45 cycles) and that THC-induced
cell death was prevented by the CB2-selective antagonist
SR144528 but not by the CB1-selective antagonist
SR141716 (Fig. 1A). Here, we investigated whether coupling
of the CB2 receptor to MAPKs participates in this eﬀect. As
shown in Fig. 1B, incubation with THC led to activation of
ERK, JNK and p38 MAPK. Pharmacological inhibition of
p38 MAPK but not of ERK or JNK signiﬁcantly prevented
THC-induced apoptosis of Jurkat cells (Fig. 1C, E and F).In line with that observation, THC treatment activated p38
MAPK and SR144528 but not SR141716 prevented this ef-
fect (Fig. 1D). The CB2-selective agonist JWH-133 [19] at
10 lM reduced cell viability by 39 ± 10% (6 h, n = 4) and
slightly activated p38 MAPK (Fig. 1D), but for unknown
reasons its potency of action was notably lower than that
of THC.
In order to study the functional role of p38 MAPK in THC-
induced apoptosis, we sought for a system in which this
process was blunted. For this purpose, we used Jurkat cells
overexpressing the pro-survival protein Bcl-xL [17]. As shown
in Fig. 2A, Bcl-xL overexpressing Jurkat cells were resistant
to THC-induced apoptosis. Moreover, THC treatment did
not stimulate p38 MAPK in Bcl-xL overexpressing cells
and the amount of phosphorylated p38 MAPK was much
lower in Bcl-xL overexpressing than in control cells (Fig. 2B).
Taken together, these results indicate that activation of p38
MAPK kinase plays a signiﬁcant role in CB2 receptor-induced
apoptosis of Jurkat cells.
3.2. p38 MAPK is involved in CB2 receptor-induced caspases 3
and 8 activation
We have recently observed that THC treatment of Jurkat
cells leads to a CB2 receptor-dependent loss of mitochon-
drial-inner-membrane transmembrane potential (Dwm) and
cytochrome c release that lead in turn to caspases 3 and 8 acti-
vation and apoptosis (manuscript in preparation). We there-
fore investigated the involvement of p38 MAPK in these
events. Pharmacological inhibition of p38 MAPK did not pre-
vent THC-induced loss of Dwm (Fig. 3A) and only slightly
attenuated mitochondrial cytochrome c release [as a control,
pharmacological inhibition of the mitochondrial respiratory
chain with rotenone completely prevented mitochondrial cyto-
chrome c release (Fig. 3B) – but did not aﬀect p38 MAPK
phosphorylation (Fig. 3C)]. In contrast, incubation with
PD169316 signiﬁcantly prevented caspases 3 (Fig. 4A and B)
and 8 (Fig. 4D and E) activation as well as cleavage of the cas-
pase 3 selective substrate PARP (Fig. 4C) and the caspase 8
substrate Bid (Fig. 4F). The notion that p38 MAPK may play
a role in caspase activation is in line with previous observa-
tions in other cellular systems [20] and suggest that, upon can-
nabinoid challenge, p38 MAPK is involved in regulating the
activation of caspases 3 and 8 rather than in acting as a pri-
mary regulator of the mitochondrial events that trigger cyto-
chrome c release.
3.3. Concluding remarks
Activation of cannabinoid receptors has been shown to
induce apoptosis in diﬀerent tumour cells. Nevertheless, the
molecular mechanisms involved in this eﬀect are not
completely understood yet. It has been recently reported that
activation of the CB2 receptor induces apoptosis in the human
leukaemia cell line Jurkat [12]. Here, we show that activation
of p38 MAPK participates in this eﬀect. Cannabinoid
receptors induce apoptosis via sustained ERK activation [5]
and Akt inhibition [21]. JNK has also been implicated in the
pro-apoptotic eﬀect of cannabinoids [22]. However, although
p38 MAPK is coupled to CB1 [14,15] and CB2 [23] receptors,
and this kinase has been repeatedly shown to participate in
programmed cell death [24], this is the ﬁrst time in that p38
MAPK is shown to participate in cannabinoid receptor-induced
Fig. 1. p38 MAPK is involved in CB2 receptor-induced apoptosis. Panel A: Cells were pre-incubated with vehicle (), 1 lM SR141716 (SR1) or
2 lM SR144258 (SR2) for 20 min, further treated with vehicle (C) or 1.5 lM THC for 2 h, and cell viability was determined by Trypan blue
exclusion. Results correspond to 4 diﬀerent experiments and are expressed as the percentage of viable cells relative to vehicle-treated cells. Panel B:
Cells were incubated with 1.5 lM THC for the times indicated, cell extracts were obtained and phospho-ERK, phospho-JNK, phospho-p38 MAPK
and a-tubulin content was analyzed by Western blot. Panel C: Cells were pre-incubated with vehicle (), 0.4 lM PD169316 (a selective p38 MAPK
inhibitor), 10 lM SP600125 (a selective JNK inhibitor) or 25 lM PD98059 (a selective ERK pathway inhibitor) for 20 min, and further treated with
vehicle (C) or 1.5 lM THC for 1 h. Apoptosis was then analyzed by ﬂow cytometry. Results correspond to 6 diﬀerent experiments and are expressed
as the percentage of hypodiploid cells relative to vehicle-treated cells. Panel D: Cells were pre-incubated with vehicle (), 1 lM SR141716 (SR1) or
2 lM SR144258 (SR2) for 20 min, and further treated with vehicle (C), 1.5 lM THC or 10 lM JWH-133 (JWH) for 15 min. Cell extracts were then
obtained and phospho-p38 an a-tubulin content was analyzed by Western blot. Representative experiments and optical density values relative to
loading controls are shown. Panels E and F: Cells were pre-incubated with vehicle () or 2 lM PD169316 for 20 min, and further treated with vehicle
(C) or 1.5 lMTHC for 1 h. Apoptosis was then determined by ﬂow cytometry. Results correspond to 3 diﬀerent experiments and are expressed as the
percentage of annexin V-positive/propidium iodide (PI)-negative cells relative to vehicle-treated cells (panel E). A dot plot of a representative
experiment is shown. Values in the lower-right corner of each plot indicate the percentage of annexin V-positive/PI-negative cells (panel F).
*Signiﬁcantly diﬀerent (P < 0.01) from vehicle-treated cells. #Signiﬁcantly diﬀerent (P < 0.01) from cells treated only with THC.
Fig. 2. THC does not stimulate p38 MAPK in Bcl-xL overexpressing cells. Panel A: Control (JK) and Bcl-xL overexpressing (JK-Bcl-xL) Jurkat cells
were treated with vehicle or 1.5 lM THC for 1 h, and nuclear DNA content was analyzed by ﬂow cytometry. Results correspond to 3 diﬀerent
experiments and are expressed as the percentage of hypodiploid cells relative to the corresponding vehicle-treated cells. Panel B: JK and JK-Bcl-xL
cells were pre-incubated with vehicle or 0.4 lM PD169316 for 20 min, and further treated with vehicle (C) or 1.5 lM THC for 15 min. Cell extracts
were then obtained and phospho-p38 and total p38 content was analyzed by Western blot. Optical density values relative to loading controls are
shown. A representative experiment of 3 is shown. *Signiﬁcantly diﬀerent (P < 0.01) from the respective vehicle-treated cells. #Signiﬁcantly diﬀerent
(P < 0.01) from control-JK cells.
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Fig. 3. p38 MAPK does not aﬀect apoptotic mitochondrial events. Panel A: Cells were pre-incubated with vehicle () or 2 lM PD169316 for 20 min,
further treated with vehicle (C) or 1.5 lM THC for 15 min, and mitochondrial transmembrane potential changes were analyzed by ﬂow cytometry.
Results correspond to 3 diﬀerent experiments and are expressed as the percentage of hypopolarized cells relative to vehicle-treated cells. Panels B and
C: Cells were pre-incubated with vehicle (), 2 lM PD169316 or 20 lM rotenone (ROT) for 20 min, and further treated with vehicle (C) or 1.5 lM
THC for 15 min. Cytosolic fractions were isolated and cytochrome c (cyt c) content was analyzed by Western blot (panel B) or cell extracts were
obtained and phospho-p38 an a-tubulin content was analyzed by Western blot (panel C). A representative experiment of 3 is shown in each panel.
Optical density values relative to loading controls are shown. *Signiﬁcantly diﬀerent (P < 0.01) from vehicle-treated cells.
Fig. 4. p38 MAPK is involved in THC-induced caspases 3 and 9 activation. Panels A and D: Cells were treated with 1.5 lM THC for the indicated
times and DVEDase (caspase 3/7, panel A) and LETDase (caspase 8, panel D) activities were assayed at each time point. Results correspond to 4
diﬀerent experiments and are expressed as the percentage of caspase 3 or 8 activity relative to vehicle-treated cells. Panels B and E: Cells were pre-
incubated with vehicle () or 2 lM PD169316 for 20 min, further treated with vehicle (C) or 1.5 lM THC for 1 h, and DVEDase (caspase 3/7, panel
B) and LETDase (caspase 8, panel E) activities were assayed. Results correspond to 4 diﬀerent experiments and are expressed as the percentage of
caspase activity related to vehicle-treated cells. Panels C and F: Cells were pre-incubated with vehicle () or 2 lM PD169316 for 20 min, and further
treated with vehicle (C) or 1.5 lM THC for 1 h (panel C) or 30 min (panel F). Cell extracts were obtained and PARP, procaspase 3 and a-tubulin
(panel C) or truncated Bid (tBid, panel F) were determined. A signiﬁcant experiment of 2 is shown. *Signiﬁcantly diﬀerent (P < 0.01) from vehicle-
treated cells. #Signiﬁcantly diﬀerent (P < 0.01) from cells treated only with THC.
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induced apoptosis of glioma [5] and dendritic [25] cells does
not depend on p38 MAPK activation. In contrast, ERK and
JNK are not apparently involved in THC-induced apoptosisof Jurkat cells. Nevertheless, further research is still necessary
to elucidate the molecular bases of the activation of the diﬀer-
ent MAPK cascades in the context of CB2 receptor-induced
apoptosis.
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